Top 31 Lung Cancer treatment startups

Oct 21, 2024 | By Jason Kwon

These startups develop new lung cancer treatments and diagnostics technologies, such as robot-assisted surgery, targeted therapy, immunotherapy, stereotactic body radiation therapy, cryoablation, proton therapy, radiofrequency ablation.
1
Country: USA | Funding: $2.4M
Peer Medical allows lung cancer patients to anonymously share treatments with each other
2
Country: USA | Funding: $3.9B
At Moderna, we are pioneering the development of a new class of drugs made of messenger RNA (mRNA). This novel drug platform builds on the discovery that modified mRNA can direct the body’s cellular machinery to produce nearly any protein of interest, from native proteins to antibodies and other entirely novel protein constructs that can have therapeutic activity inside and outside of cells.
3
Country: USA | Funding: $1.6B
IOVANCE Biotherapeutics is focused on the development and commercialization of autologous cellular immunotherapies optimizing personalized, tumor-directed Tumor Infiltrating Lymphocytes (TIL)
4
Country: USA | Funding: $1.3B
Fate Therapeutics is a stem cell and developmental biology research company using biological mechanisms to develop stem cell therapeutics.
5
Country: USA | Funding: $749.5M
Nuvalent is a biotechnology company that develops targeted therapies for clinically proven kinase targets in cancer.
6
Country: USA | Funding: $733.3M
Auris Health is developer of robotic microsurgical devices designed for ophthalmic procedures that help diagnose cancer using controllers.
7
Country: USA | Funding: $325M
Obsidian Therapeutics is a developer of a next-generation cell and gene therapies created to extend adoptive immunotherapy.
8
Country: USA | Funding: $313M
Bicara Therapeutics develops dual-action cancer therapies, combining targeted treatments with tumor modulators for enhanced impact.
9
Country: USA | Funding: $219.5M
Epic Sciences is a diagnostics company improving cancer management by providing real-time biopsy material to guide personalized medicine.
10
Country: Denmark | Funding: $160.4M
Galecto develops galectin modulators for the treatment of severe diseases, including fibrosis and cancer. The company builds on more than 10 years of research into galectins and galectin modulators, which combined with a strong patent estate gives Galecto Biotech a unique platform.
11
Country: Canada | Funding: $141.4M
Kintara Therapeutics is engaged in developing and commercializing therapies for the treatment of cancer patients.
12
Country: USA | Funding: $106M
Totus Medicines is a provider of chemical biology technologies by creating life-changing covalent drugs.
13
Country: China | Funding: $101.6M
Juventas is a provider and developer of innovative immune cell therapeutic drugs.
14
Country: USA | Funding: $95M
Lantern Pharma is a clinical stage pharmaceutical company developing new classes of precision cancer drugs with novel mechanisms of action.
15
Country: USA | Funding: $89.4M
Genprex is a clinical stage gene therapy company developing molecular therapies to better target lung cancer cells. Their new approach to treating cancer is based upon our novel proprietary technology platform, including our initial product candidate, Oncoprex immunogene therapy, or Oncoprex.
16
Country: USA | Funding: $82.4M
Rain Therapeutics is a biotech company laser focused on a subtype of non-small cell lung cancer
17
Country: USA | Funding: $75M
OncoMyx Therapeutics develops oncolytic immunotherapies to orchestrate an immune response and treat cancer.
18
Country: USA | Funding: $73M
OncoCyte focused on cancers with large patient populations and significant unmet need. The company is developing three genetic tests – blood tests for breast cancer and lung cancer, and a urine-based test for bladder cancer.
19
Country: USA | Funding: $65M
Actuate Therapeutics is a biopharmaceutical company focused on the development of compounds for use in the treatment of cancer, and inflammatory diseases leading to fibrosis and neurodegeneration. Our work has led to some fascinating results around anti-tumor activity in the brain, pancreas, lungs, and breasts.
20
Country: UK | Funding: $52M
Iksuda Therapeutics is a biotechnology company specializing in the development of next generation biotherapeutics
Editor: Jason Kwon
Jason Kwon is a senior editor for MedicalStartups. He has previously covered the pharmaceutical and medical research industries for FDAnews and worked as a head of marketing for medical startup Sonic Therapeutics. Before that, he co-founded a startup consulting business for emerging entrepreneurial hubs in Asia. Jason graduated from St. Bonaventure University’s journalism school. In his free time, Jason enjoys yoga, watching movie trailers, traveling to places where he can't get cell service. You can contact Jason at jaskwon(at)medicalstartups(dot)com